Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 66 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast CancerStatus unknownNCT04034823Phase 2
• A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLCActive, not recruitingNCT04033354Phase 3
• A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell CarcinomaCompletedNCT04028245Early Phase 1
• Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue SarcomasActive, not recruitingNCT04028063Phase 2
• A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung CancerCompletedNCT04028050Phase 3
• Chidamide Combined With Toripalimab in SarcomaCompletedNCT04025931Phase 2
• NeoVax With Nivolumab in Patients With Ovarian CancerActive, not recruitingNCT04024878Phase 1
• Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast CancerStatus unknownNCT04024800Phase 2
• A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLCStatus unknownNCT04023617Phase 2
• Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS LymphomaCompletedNCT04022980Phase 1
• Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With MelanomaStatus unknownNCT04021420Phase 1/2
• Neoadjuvant Atezolizumab in Cutaneous MelanomaActive, not recruitingNCT04020809Phase 1
• Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal CancerActive, not recruitingNCT04017650Phase 1/2
• Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)Active, not recruitingNCT04017455Phase 2
• A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in ChinaActive, not recruitingNCT04015778Phase 2
• Tri Association in Patient With Advanced Epithelial Ovarian Cancer in RelapseStatus unknownNCT04015739Phase 2
• Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO StudyStatus unknownNCT04014530Phase 1/2
• SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular CarcinomaStatus unknownNCT04014101Phase 2
• Adjuvant Treatment Determined By Pathological Response To Neoadjvuant NivolumabActive, not recruitingNCT04013854Phase 2
• Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung CancerActive, not recruitingNCT04013542Phase 1
• Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant TumorsStatus unknownNCT04010071Phase 2
• Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET ScanningActive, not recruitingNCT04009967Phase 2
• A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid TumorsTerminatedNCT04009460Phase 1
• Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid TumorsActive, not recruitingNCT04007744Phase 1
• A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV MelanomaWithdrawnNCT04007588Phase 2
• PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric AdenocarcinomaStatus unknownNCT04006821Phase 2
• Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.Active, not recruitingNCT04006262Phase 2
• Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal CancerStatus unknownNCT04006041Phase 2
• Combination of Toripalimab and Chemoradiotherapy in Esophageal CancerCompletedNCT04005170Phase 2
• Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial CarcinomaActive, not recruitingNCT04004442Phase 1
• A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTCStatus unknownNCT04004234Phase 1/2
• Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell LymphomaTerminatedNCT04002622Phase 2
• Therapy for High-Risk HPV 16-Positive Oropharynx Cancer PatientsWithdrawnNCT04001413Phase 2
• Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung CancerActive, not recruitingNCT03999710Phase 2
• A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory MalignanciesWithdrawnNCT03999658Phase 2
• Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in ChinaStatus unknownNCT03998345Not applicable
• Study of TQB2450 Combined With Anlotinib in Subjects With Advanced CholangiocarcinomaStatus unknownNCT03996408Phase 1/2
• A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced TumorsCompletedNCT03995472Phase 1
• Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell LymphomaActive, not recruitingNCT03995147Phase 2
• Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal AdenocarcinomaStatus unknownNCT03995017Phase 1/2
• Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLCStatus unknownNCT03994744Phase 2
• Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.Status unknownNCT03994393Phase 2
• Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing CystectomyStatus unknownNCT03993249Phase 2
• Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine CarcinomaStatus unknownNCT03992911Phase 2/3
• Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Acral Malignant MelanomaStatus unknownNCT03991975Phase 1/2
• Study of Olaparib and Durvalumab in IDH-Mutated Solid TumorsActive, not recruitingNCT03991832Phase 2
• Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung CancerActive, not recruitingNCT03991819Phase 1
• A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or LymphomasStatus unknownNCT03991559Phase 1
• Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLCStatus unknownNCT03991403Phase 3
• Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B MutationActive, not recruitingNCT03989089Phase 2
• A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)CompletedNCT03988036Phase 2
• Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLCStatus unknownNCT03987867Phase 1
• Neoadjuvant Nivolumab for Operable Esophageal CarcinomaStatus unknownNCT03987815Phase 2
• A Study of PSB205 in Subjects With Advanced Solid TumorsStatus unknownNCT03986606Phase 1
• Apatinib Plus SHR1210 in Advanced Mucosal MelanomaStatus unknownNCT03986515Phase 2
• Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCCCompletedNCT03985046Phase 2
• Window of Opportunity Study in Colorectal CancerCompletedNCT03984578Phase 2
• Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.Active, not recruitingNCT03983954Phase 1
• Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung CancerStatus unknownNCT03983928Phase 1/2
• Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic CancerCompletedNCT03983057Phase 2
• Toripalimab Combined With Gemcitabine/5--fluoropyrimidine for Advanced CholangiocarcinomaStatus unknownNCT03982680Phase 2
• Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid TumorsWithdrawnNCT03982173Phase 2
• PDR001 + Panobinostat for Melanoma and NSCLCWithdrawnNCT03982134Phase 1
• Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and ChemotherapyWithdrawnNCT03982121Phase 1
• Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast CancerTerminatedNCT03982004Phase 1
• A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial CancerActive, not recruitingNCT03981796Phase 3
• A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete ResectionCompletedNCT03980314Phase 1
• A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) TreatmentTerminatedNCT03978611Phase 1
• Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel ChemotherapyActive, not recruitingNCT03977194Phase 3
• Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal CancerStatus unknownNCT03977090Phase 1
• Safety and Efficacy of Genolimzumab (GB226) in Combination With FruquintinibStatus unknownNCT03976856Phase 1
• Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)CompletedNCT03976518Phase 2
• Sintilimab in Combination With Nab-paclitaxel in Patients With HNSCC (Head and Neck Squamous Cell Carcinoma )Status unknownNCT03975270Phase 2
• Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 AntibodyStatus unknownNCT03975036Phase 2/3
• Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant GliomaWithdrawnNCT03973879Phase 1/2
• A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) PatientsStatus unknownNCT03973112Phase 2
• Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical CancerStatus unknownNCT03972722Phase 2
• A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular CarcinomaTerminatedNCT03970616Phase 1/2
• Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic CancerCompletedNCT03970252Early Phase 1
• Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or RefractorySuspendedNCT03969446Phase 1
• Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell CarcinomaActive, not recruitingNCT03969004Phase 3
• Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial CarcinomaActive, not recruitingNCT03967977Phase 3
• Safety and Efficacy of PD-1 Inhibitors in Patients With Liver TransplantStatus unknownNCT03966209Phase 1
• Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal AdenocarcinomaStatus unknownNCT03966118Phase 2
• Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLCActive, not recruitingNCT03965468Phase 2
• TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast CancerActive, not recruitingNCT03964532Phase 1/2
• A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)CompletedNCT03964233Phase 1
• A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLCTerminatedNCT03963414Phase 1
• Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBMCompletedNCT03961971Phase 1
• Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction AdenocarcinomaActive, not recruitingNCT03959293Phase 2
• A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)Status unknownNCT03958890Phase 3
• TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial CancerActive, not recruitingNCT03955978Phase 1
• PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral MelanomaStatus unknownNCT03955354Phase 2
• A Trial Evaluating Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following ChemoradiationCompletedNCT03955198Phase 2
• A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid TumorsCompletedNCT03954067Phase 1
• A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT03952403Phase 3
• REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate CancerActive, not recruitingNCT03951831Phase 2
• Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic CholangiocarcinomaStatus unknownNCT03951597Phase 2
• Durvalumab and Olaparib in Metastatic or Recurrent Endometrial CancerStatus unknownNCT03951415Phase 2
• Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder CancerStatus unknownNCT03950362Phase 2

← Immune Checkpoint Inhibitors overview